Real-World Evidence on Adverse Events and Healthcare Resource Utilization in Patients with Chronic Lymphocytic Leukaemia in Spain Using Natural Language Processing: The SRealCLL Study.

Authors: Abrisqueta-Costa, Pau¹ (AUTHOR) pabrisqueta@vhio.net, García-Marco, José Antonio² (AUTHOR) jagarciam@aehh.org, Gutiérrez, Antonio³ (AUTHOR) antoniom.gutierrez@ssib.es, Hernández-Rivas, José Ángel⁴ (AUTHOR) jahernandezr@salud.madrid.org, Andreu-Lapiedra, Rafael⁵ (AUTHOR) andreu_raflap@gva.es, Arguello-Tomas, Miguel⁶ (AUTHOR) marguello@santpau.cat, Leiva-Farré, Carolina⁷ (AUTHOR) carolina.leiva@astrazeneca.com, López-Roda, María Dolores⁷ (AUTHOR) angel.callejo@astrazeneca.com, Callejo-Mellén, Ángel⁷ (AUTHOR) esther.alvarez@astrazeneca.com, Álvarez-García, Esther⁷ (AUTHOR), Loscertales, Javier⁸ (AUTHOR) javier.loscertales@salud.madrid.org

Source: Cancers. Dec2024, Vol. 16 Issue 23, p4004. 15p.

Subject Terms: *THERAPEUTIC use of antineoplastic agents, *HEMORRHAGE risk factors, *CHRONIC lymphocytic leukemia, *MEDICAL care use, *PUBLIC hospitals, *PROTEIN kinase inhibitors, *ANEMIA, *RISK assessment, *RESEARCH funding, *CANCER relapse, *CYTOPENIA, *CANCER patient medical care, *NATURAL language processing, *TREATMENT effectiveness, *RITUXIMAB, *THROMBOCYTOPENIA, *ELECTRONIC health records, *RICHTER syndrome, *DRUG resistance, *DISEASE risk factors, *DISEASE complications

Geographic Terms: SPAIN

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

Authors: Abrisqueta, Pau, González-Barca, Eva, Ferrà, Christelle, Ríos-Herranz, Eduardo, Fernández de la Mata, Margarita, Delgado, Julio, Andreu, Rafael, Hernández-Rivas, José Ángel, Terol, María José, Navarro, Almudena, Vidriales, M. Belén, Baltasar, Patricia, De la Serna, Javier, Ramírez, Ángel, Ballester, Carmen, Moreno, Carol, García-Marco, José Antonio, Córdoba, Raúl, Yáñez, Lucrecia, Casado, Luís Felipe, González, Marcos, Bosch, Francesc

Source: In eClinicalMedicine July 2024 73

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Authors: Roeker, Lindsey E. ^{1, *}, Eyre, Toby A. ^{2, *}, Thompson, Meghan C. ¹, Lamanna, Nicole ³, Coltoff, Alexander R. ³, Davids, Matthew S. ⁴, Baker, Peter O. ⁴, Leslie, Lori ⁵, Rogers, Kerry A. ⁶, Allan, John N. ⁷, Cordoba, Raul ⁸, Lopez-Garcia, Alberto ⁸, Antic, Darko ⁹, Pagel, John M. ¹⁰, Martinez-Calle, Nicolas ¹¹, García-Marco, José Antonio ¹², Hernández‐Rivas, Jose‐Ángel ¹³, Miras, Fatima ¹⁴, Coombs, Catherine C. ¹⁵, Österborg, Anders ¹⁶, Hansson, Lotta ¹⁶, Seddon, Amanda N. ¹⁷, López Jiménez, Javier ¹⁸, Wilson, Matthew R. ¹⁹, El-Sharkawi, Dima ²⁰, Wojenski, Daniel ²¹, Ma, Shuo ²¹, Munir, Talha ²², Valenciano, Susana ²³, Seymour, Erlene ²⁴, Barr, Paul M. ²⁵, Pu, Jeffrey ²⁶, Patten, Piers E.M. ²⁷, Perini, Guilherme F. ²⁸, Huntington, Scott F. ²⁹, Parry, Helen ³⁰, Sundaram, Suchitra ³¹, Skarbnik, Alan ³², Kamdar, Manali ³³, Jacobs, Ryan ³⁴, Walter, Harriet ³⁵, Walewska, Renata ³⁶, Broom, Angus ³⁷, Lebowitz, Sonia ¹, Isaac, Krista M. ³⁸, Portell, Craig A. ³⁸, Ahn, Inhye E. ³⁹, Ujjani, Chaitra S. ⁴⁰, Shadman, Mazyar ⁴⁰, Skånland, Sigrid S. ⁴¹, Chong, Elise A. ⁴², Mato, Anthony R. ^{1, *}

Source: In Blood 4 November 2021 138(18):1768-1773

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Authors: Mato, Anthony R. ^{1, 1, *}, Roeker, Lindsey E. ^{1, *}, Lamanna, Nicole ², Allan, John N. ³, Leslie, Lori ⁴, Pagel, John M. ⁵, Patel, Krish ⁵, Osterborg, Anders ⁶, Wojenski, Daniel ⁷, Kamdar, Manali ⁸, Huntington, Scott F. ⁹, Davids, Matthew S. ¹⁰, Brown, Jennifer R. ¹⁰, Antic, Darko ¹¹, Jacobs, Ryan ¹², Ahn, Inhye E. ¹³, Pu, Jeffrey ¹⁴, Isaac, Krista M. ¹⁵, Barr, Paul M. ¹⁶, Ujjani, Chaitra S. ¹⁷, Geyer, Mark B. ¹, Berman, Ellin ¹, Zelenetz, Andrew D. ¹, Malakhov, Nikita ³, Furman, Richard R. ³, Koropsak, Michael ⁴, Bailey, Neil ⁵, Hanson, Lotta ⁶, Perini, Guilherme F. ¹⁸, Ma, Shuo ⁷, Ryan, Christine E. ¹⁰, Wiestner, Adrian ¹³, Portell, Craig A. ¹⁵, Shadman, Mazyar ¹⁷, Chong, Elise A. ¹⁹, Brander, Danielle M. ²⁰, Sundaram, Suchitra ²¹, Seddon, Amanda N. ²², Seymour, Erlene ²³, Patel, Meera ²³, Martinez-Calle, Nicolas ²⁴, Munir, Talha ²⁵, Walewska, Renata ²⁶, Broom, Angus ²⁷, Walter, Harriet ²⁸, El-Sharkawi, Dima ²⁹, Parry, Helen ³⁰, Wilson, Matthew R. ³¹, Patten, Piers E.M. ³², Hernández-Rivas, José-Ángel ³³, Miras, Fatima ³⁴, Fernández Escalada, Noemi ³⁵, Ghione, Paola ¹, Nabhan, Chadi ³⁶, Lebowitz, Sonia ¹, Bhavsar, Erica ³, López-Jiménez, Javier ³⁷, Naya, Daniel ³⁸, Garcia-Marco, Jose Antonio ³⁹, Skånland, Sigrid S. ⁴⁰, Cordoba, Raul ⁴¹, Eyre, Toby A. ⁴²

Source: In Blood 3 September 2020 136(10):1134-1143

Minimal residual disease in chronic lymphocytic leukaemia

Alternate Title: Enfermedad mínima residual en la leucemia linfocítica crónica (Spanish; Castilian)

Authors: García Vela, José Antonio, García Marco, José Antonio

Source: In Medicina Clínica (English Edition) 23 February 2018 150(4):144-149

Enfermedad residual mínima en la leucemia linfática crónica

Alternate Title: Minimal residual disease in chronic lymphocytic leukaemia (English)

Authors: García Vela, José Antonio, García Marco, José Antonio

Source: In Medicina Clinica 23 February 2018 150(4):144-149

Sequential Quantification of T-Cell Receptor Excision Circles (TREC) and K-Deleting Recombination Excision Circles (KREC) in Allogeneic HSCT Recipients

Authors: de Miguel, Carlos, Briansó, Ferran, Trillo, Rosalia Alonso, Martín-Buitrago, Lucía Nuñez, Martínez-Muñoz, María Esther, Bautista, Guiomar, Manchado-Perdiguero, Carlos, García-Marco, José Antonio, Sánchez-Peral, Ali, Duarte, Rafael F.

Source: Transplantation and Cellular Therapy. 29(S):S66-S67

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100180675273.0x000001&indx=1&recIds=ETOCvdc_100180675273.0x000001

Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study.

Authors: Loscertales, Javier, Abrisqueta-Costa, Pau, Gutierrez, Antonio, Hernández-Rivas, José Ángel, Andreu-Lapiedra, Rafael, Mora, Alba, Leiva-Farré, Carolina, López-Roda, María Dolores, Callejo-Mellén, Ángel, Álvarez-García, Esther, García-Marco, José Antonio

Source: Cancers; Aug2023, Vol. 15 Issue 16, p4047, 13p

Subject Terms: CHRONIC lymphocytic leukemia treatment, NATURAL language processing, MACHINE learning, ARTIFICIAL intelligence, SYMPTOMS, DESCRIPTIVE statistics, RESEARCH funding, ELECTRONIC health records, COMORBIDITY

Geographic Terms: SPAIN

Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica

Alternate Title: Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia (English)

Authors: Felipe Casado, Luis, García Marco, José Antonio, Gilsanz, Florinda, González, Marcos, Ríos, Eduardo, de la Serna, Javier, Urbano, Álvaro, Vicente, Vicente, Rubio-Terrés, Carlos, Castro, Antonio J.

Source: In Gaceta Sanitaria 2011 25(4):274-281

CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia

Authors: Citores, Maria Jesus, Castejon, Raquel, Villarreal, Mercedes, Rosado, Silvia, Garcia-Marco, Jose Antonio, Vargas, Juan Antonio

Source: In Experimental Hematology 2010 38(3):165-173

79 - Sequential Quantification of T-Cell Receptor Excision Circles (TREC) and K-Deleting Recombination Excision Circles (KREC) in Allogeneic HSCT Recipients

Authors: de Miguel, Carlos, Briansó, Ferran, Trillo, Rosalia Alonso, Martín-Buitrago, Lucía Nuñez, Martínez-Muñoz, María Esther, Bautista, Guiomar, Manchado-Perdiguero, Carlos, García-Marco, José Antonio, Sánchez-Peral, Ali, Duarte, Rafael F.

Source: In Transplantation and Cellular Therapy February 2023 29(2) Supplement:S66-S67

Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia.

Authors: Jiménez, Isabel, Tazón-Vega, Bárbara, Abrisqueta, Pau, Nieto, Juan C., Bobillo, Sabela, Palacio-García, Carles, Carabia, Júlia, Valdés-Mas, Rafael, Munuera, Magdalena, Puigdefàbregas, Lluís, Parra, Genís, Esteve-Codina, Anna, Franco-Jarava, Clara, Iacoboni, Gloria, Terol, María José, García-Marco, José Antonio, Crespo, Marta, Bosch, Francesc

Source: Biomarker Research; 5/20/2021, Vol. 9 Issue 1, p1-14, 14p

Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative.

Authors: Bosch, Francesc, Navarro, Blanca, Crespo, Marta, Alcoceba, Miguel, Sánchez, Julio Bravo, Tazón, Barbara, Serrano, Alicia, Álvarez, María García, Serrano, Lydia González, Alonso-Torres, Pablo, Villanueva, Miguel, Loriente, Cristina, Abrisqueta, Pau, Peiró, Manel, García-Marco, José Antonio, González, Marcos, Terol, María José

Source: Annals of Hematology; Mar2021, Vol. 100 Issue 3, p825-830, 6p

Subject Terms: CHRONIC lymphocytic leukemia, CHRONIC leukemia, GENES

Geographic Terms: SPAIN

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Prostatic-Like Syndrome in a Woman with Chronic Lymphocytic Leukemia: Sequential Kinase Inhibitor Therapy.

Authors: Velasco-Rodríguez, Diego, Piris-Villaespesa, Miguel, Soteras, Carmen, Vallés, Ana, García-Marco, José Antonio, García-Vela, José Antonio

Source: Case Reports in Hematology; 7/2/2017, p1-3, 3p

Subject Terms: KINASE inhibitors, DISEASE remission, DISEASE relapse, PROSTATE diseases, THERAPEUTICS

Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.

Authors: Espinet, Blanca, Salaverria, Itziar, Beà, Sílvia, Ruiz-Xivillé, Neus, Balagué, Olga, Salido, Marta, Costa, Dolors, Carreras, Joaquim, Rodríguez-Vicente, Ana Eugenia, Luís García, Juan, Hernández-Rivas, Jesús María, Calasanz, María José, Siebert, Reiner, Ferrer, Ana, Salar, Antonio, Carrió, Ana, Polo, Natividad, García-Marco, José Antonio, Domingo, Alicia, González-Barca, Eva

Source: Genes, Chromosomes & Cancer; May2010, Vol. 49 Issue 5, p439-451, 13p

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Authors: Abrisqueta, Pau ^*, Villamor, Neus, Terol, María José ^*, González-Barca, Eva ^*, González, Marcos ^*, Ferrà, Christelle ^*, Abella, Eugenia ^*, Delgado, Julio ^*, García-Marco, Jose Antonio ^*, González, Yolanda ^*, Carbonell, Felix, Ferrer, Secundino ^*, Monzo, Encarna ^*, Jarque, Isidro ^*, Muntanola, Ana ^*, Constants, Mireia ^*, Escoda, Lourdes ^*, Montserrat, Emili, Bosch, Francesc

Source: In Blood 16 November 2012 120(21):3930-3930

Fe de errores de “Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica”

Alternate Title: Erratum to “Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia” (English)

Authors: Casado, Luis Felipe, García Marco, José Antonio, Gilsanz, Florinda, González, Marcos, Ríos, Eduardo, de la Serna, Javier, Urbano, Álvaro, Vicente, Vicente, Rubio-Terrés, Carlos, Castro, Antonio J.

Source: In Gaceta Sanitaria 2011 25(5):444-444

This result is not displayed to guests.
Login for full access.